Vaccine Partnership with FioCruz

Partnership Objective

Technology transfer and product supply agreements for polio, MMR, Rotavirus and pneumococcal vaccines.

This partnership is and is helping to ensure that the annual cohort of 3.5 million babies in Brazil will be protected. This partnership is and is helping to ensure that the annual cohort of 3.5 million babies in Brazil will be protected. Copyright GlaxoSmithKline

Partnership Description

GlaxoSmithKline has been partnering with Brazil’s Oswaldo Cruz Foundation (FioCruz) since 1985 to manufacture vaccines for public health priorities in Brazil including polio, Haemophilus influenzae type b (Hib), measles, mumps, rubella, rotavirus and, most recently, pneumococcal disease.

To address pneumococcal disease in Brazil, GlaxoSmithKline will provide FioCruz with access to the technology behind its SynflorixTM vaccine which protects against life-threatening pneumonia, meningitis and bacteraemia infections. GlaxoSmithKline will supply SynflorixTM to FioCruz until the technology transfer is completed. The deal benefits both GlaxoSmithKline and FioCruz and is helping to ensure that the annual cohort of 3.5 million babies in Brazil will be protected by GlaxoSmithKline's and Fiocruz vaccines.

Lessons learned

  • Build trust at all levels of workforce and management;
  • Emphasize on matrix organization and project team way of working;
  • Do not under-estimate Quality Control, QA and safety data management;
  • Develop people by training and empowerment;
  • Learning by doing and the learning curve.       

Partnership information

Company(ies) GlaxoSmithKline

Partner(s) Brazilian Ministry of Health, Fundação Oswaldo Cruz (Fiocruz)

Type of Partner(s) Government, NGOs

Therapeutic Focus Women and Children's Health, Vaccine-Preventable Diseases

Disease(s) Children's Health, Influenza, Measles, Mumps, Pneumonia, Polio, Rotavirus, Rubella

Program Type(s) Availability of Treatment - Differential Pricing, Availability of Treatment - Technology Transfer - Manufacturing and Entrepreneurial Know-How, Prevention Programs - Vaccines

Targeted Population(s) Children, Elderly, General population, Men, Mothers, People with low income, Women, Youth

Region(s) Latin America & Caribbean

Number of Countries 1

Country(ies) Brazil

Start Date 1985

More information GSK Health for All

Anticipated completion date Ongoing